Clinical Trials Logo

Lower Limb Fracture clinical trials

View clinical trials related to Lower Limb Fracture.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05999890 Completed - Lower Limb Fracture Clinical Trials

Comparison of Postoperative Analgesia Between Intravenous Paracetamol and Intranasal Tapentadol

Start date: July 5, 2021
Phase: Phase 4
Study type: Interventional

The aim of the study was to compare the analgesic efficacy of intranasal tapentadol nasal spray 44.5mg and intravenous paracetamol 1gm during the postoperative period by Visual analog scale(VAS)in patients undergoing lower limb(long bone fractures)orthopedic surgeries. Paracetamol is one of the most frequently used analgesic and antipyretic agents, interferes neither with platelet nor kidney functions nor does it present the unwanted side effects of NSAIDs. Tapentadol is a novel, centrally-acting analgesic with a dual mechanism of action, combining mu-opioid receptor agonism with norepinephrine reuptake inhibition. This dual mode of action is responsible for its opioid-sparing effect, which contributes to a reduction in some of the typical opioid-related adverse effects

NCT ID: NCT05967221 Completed - Lower Limb Fracture Clinical Trials

Comparison of Postoperative Analgesia Between Intravenous Paracetamol and Intranasal Tapentadol

Start date: July 5, 2021
Phase: Phase 4
Study type: Interventional

Aim of the study to compare the analgesic efficacy of intranasal tapentadol nasal spray 44.5mg and intravenous paracetamol 1gm during postoperative period by Visual analogue scale(VAS)in patients undergoing lower limb(long bone fractures)orthopedic surgeries. Paracetamol is one of the most frequently used analgesic and antipyretic agent, interferes neither with platelet nor kidney functions nor does it present the unwanted side effects of NSAIDS. Tapentadol is a novel, centrally acting analgesic with dual mechanism of action, combining mu-opioid receptor agonism with norepinephrine reuptake inhibition.this dual mode of action is responsible for its opioid sparing effect, which contributes to reduction in some of the typical opioid related adverse effects.

NCT ID: NCT04675372 Completed - Nerve Block Clinical Trials

Dexmedetomidine Facilitate Analgesia

Start date: January 19, 2021
Phase: Phase 4
Study type: Interventional

Pre-clinic evidences showed that DEX produces antinociception by inhibiting the activation of spinal microglia and astrocyte decreasing noxious stimuli evoked release of nociceptive substances and further interrupting the spinal neuron-glia cross talk and regulating the nociceptive transmission under chronic pain condition. in this study, the analgesic efficacy of Dexmedetomidine was evaluated by a new non-invasive nociceptive index (qNOX). In this study, Anagel6000 analgesia monitor was used to quantitatively compare the analgesic efficacy of Dexmedetomidine compared with Midazolam.